Moreover, we also observed that both the protein expression level and the transcript levels of hepatic EVA1A were markedly down-regulated in patients with MASLD, as revealed by immunohistochemical (IHC) staining, RT-qPCR (real-time quantitative polymerase chain reaction) analysis, and Western blot analysis (Fig. 1D to F). The gene discussed is EVA1A; the disease is metabolic dysfunction-associated steatotic liver disease.